Use of Donor-derived Cell-free DNA to Inform Tapering of Immunosuppression Therapy in Kidney Transplant Recipients: An Observational Study
| Autor: | George Osuchukwu, MD, Alexa Trevino, CMA, Sarah McCormick, PhD, Navchetan Kaur, PhD, Brittany Prigmore, MSc, Nour Al Haj Baddar, PhD, Michelle S. Bloom, PhD, Zachary Demko, PhD, Philippe Gauthier, MD, MBA |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Transplantation Direct, Vol 10, Iss 4, p e1610 (2024) |
| Druh dokumentu: | article |
| ISSN: | 2373-8731 00000000 |
| DOI: | 10.1097/TXD.0000000000001610 |
| Popis: | Background. Immunosuppression therapy (IST) is required for allograft survival but can cause significant adverse effects. Donor-derived cell-free DNA (dd-cfDNA) is a validated noninvasive biomarker for active rejection in kidney transplant (KTx). Evidence supporting dd-cfDNA testing use in IST management is limited. Methods. In this single-center observational study, dd-cfDNA testing was performed in 21 KTx patients considered good candidates for mycophenolic acid (MPA) reduction. Patients with dd-cfDNA |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|